Almirall, S.A. (BME:ALM)
11.44
0.00 (0.00%)
Mar 18, 2026, 5:35 PM CET
Almirall Revenue
In the year 2025, Almirall had annual revenue of 1.11B EUR with 12.51% growth. Almirall had revenue of 288.93M in the quarter ending December 31, 2025, with 11.37% growth.
Revenue
1.11B
Revenue Growth
+12.51%
P/S Ratio
2.20
Revenue / Employee
528.72K
Employees
2,108
Market Cap
2.46B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.11B | 123.91M | 12.51% |
| Dec 31, 2024 | 990.63M | 91.84M | 10.22% |
| Dec 31, 2023 | 898.79M | 20.28M | 2.31% |
| Dec 31, 2022 | 878.51M | 42.01M | 5.02% |
| Dec 31, 2021 | 836.50M | 22.01M | 2.70% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Grifols | 7.52B |
| Laboratorios Farmaceuticos Rovi | 743.48M |
| Faes Farma | 626.99M |
| Laboratorio Reig Jofre | 336.68M |
| Clínica Baviera | 304.91M |
| Prim, S.A. | 240.68M |
| Atrys Health | 226.24M |
| Pharma Mar | 221.39M |
Almirall News
- 6 days ago - Spain's Almirall in talks with 'dozens' of firms to license China assets, CEO says - Reuters
- 23 days ago - Almirall SA (LBTSF) Q4 2025 Earnings Call Highlights: Strong Sales Growth and Strategic Investments - GuruFocus
- 23 days ago - Almirall profit quadruples in 2025 as dermatology fuels growth push - Invezz
- 23 days ago - Q4 2025 Almirall SA Earnings Call Transcript - GuruFocus
- 23 days ago - Almirall FY25 Results Climb, Sees Growth In FY26 - Nasdaq
- 2 years ago - Almirall Delivers Strong Start of 2024 – Q1 Net Sales Growth of 6.6% Overall and 18% in the European Dermatology Business, Driven by Biologics and Solid Performance of Broad Product Portfolio - Business Wire